The Melanocortin System

The melanocortin system is a family of peptide ligands and five receptors (MC1R–MC5R) that regulate an unusually diverse set of physiological functions — skin pigmentation, appetite, energy homeostasis, sexual behavior, inflammation, and adrenal steroidogenesis. Several important therapeutic and research peptides target this system.

POMC: the precursor

Pro-opiomelanocortin (POMC) is a large precursor protein processed into multiple bioactive peptides depending on the tissue:

• α-MSH (alpha-melanocyte-stimulating hormone) — 13 amino acids. Primary MC1R and MC3R/MC4R agonist
• β-MSH and γ-MSH — less studied melanocortins
• ACTH (adrenocorticotropic hormone) — MC2R agonist, drives cortisol synthesis
• β-endorphin — opioid receptor agonist (pain modulation, reward)

The same precursor produces both a stress hormone (ACTH) and an anti-inflammatory peptide (α-MSH) — a design that tightly couples stress response with immune modulation.

The five melanocortin receptors

MC1R — Pigmentation

Location: Melanocytes (skin, hair follicles)

Function: Stimulates eumelanin production (dark pigment). MC1R activation shifts melanin synthesis from pheomelanin (red/yellow) to eumelanin (brown/black)

Peptide therapeutics: Melanotan II (non-selective MC agonist), afamelanotide (selective MC1R agonist, FDA-approved for erythropoietic protoporphyria)

MC2R — Adrenal steroidogenesis

Location: Adrenal cortex

Function: ACTH receptor. Drives cortisol, aldosterone, and adrenal androgen production

Clinical relevance: Not directly targeted by research peptides. MC2R is the ACTH receptor — its pharmacology is steroid endocrinology

MC3R — Energy homeostasis

Location: Hypothalamus, gut, immune cells

Function: Involved in energy partitioning (fat vs. lean mass), feeding behavior, and immune modulation. Less studied than MC4R

Peptide therapeutics: No selective MC3R agents in common use. Melanotan II has MC3R activity

MC4R — Appetite, energy balance, sexual function

Location: Hypothalamus (paraventricular and lateral hypothalamic nuclei), spinal cord, peripheral tissues

Function: Central regulator of appetite (MC4R activation = satiety), energy expenditure, and sexual arousal

Peptide therapeutics:

• Setmelanotide — selective MC4R agonist, FDA-approved for rare genetic obesity (POMC/PCSK1/LEPR deficiency)
• PT-141 / Bremelanotide — MC4R agonist, FDA-approved for hypoactive sexual desire disorder
• Melanotan II — non-selective MC agonist with MC4R activity (appetite suppression, sexual arousal)

MC5R — Exocrine function

Location: Exocrine glands (sebaceous, lacrimal, preputial)

Function: Regulates sebum production, pheromone signaling. The least studied MC receptor

Clinical relevance: Theoretical target for acne and seborrhea. No selective MC5R agents in clinical use

Therapeutic peptides targeting the melanocortin system

Melanotan II

Non-selective MC1R/MC3R/MC4R/MC5R agonist. Produces:

• Skin darkening (MC1R)
• Appetite suppression (MC4R)
• Sexual arousal (MC4R/MC3R)
• Potential nausea (likely MC3R/MC4R-mediated)

The non-selectivity is both its appeal (multiple effects from one peptide) and its limitation (side effects from unwanted receptor activation).

PT-141 / Bremelanotide

MC4R-preferring agonist developed from Melanotan II. FDA-approved for HSDD in premenopausal women. Unlike PDE5 inhibitors (sildenafil), bremelanotide acts centrally on sexual desire rather than peripherally on erectile mechanics.

KPV

The C-terminal tripeptide of α-MSH (Lys-Pro-Val). Retains the anti-inflammatory properties of α-MSH (NF-κB suppression) without significant MC receptor binding. Acts intracellularly rather than through surface MC receptors — a pharmacologically distinct mechanism.

Setmelanotide

Selective MC4R agonist with minimal MC1R activity. FDA-approved for genetic obesity caused by POMC, PCSK1, or LEPR deficiency — conditions where the melanocortin satiety pathway is genetically impaired. Produces 5–25% weight loss in these specific populations.

Why the melanocortin system matters

The melanocortin system is one of the most therapeutically active peptide receptor families. Understanding it explains:

• Why tanning peptides also affect appetite and sexual function (receptor non-selectivity)
• Why α-MSH fragments (KPV) have anti-inflammatory properties distinct from melanocortin receptor signaling
• Why genetic obesity from POMC pathway mutations responds to MC4R agonists but not to GLP-1 drugs
• Why bremelanotide works for desire-phase sexual dysfunction while PDE5 inhibitors address arousal-phase erectile dysfunction